AbCellera Biologics Inc.
ABCLReported to SECin USCIK 0001703057Filings at SEC EDGAR
No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.
This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 7. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.
The most recent filings
Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.
| Filed by | Type | Value | Reported | Filed by | Value | Type | Shares | Reported |
|---|---|---|---|---|---|---|---|---|
| Hayden Michael R— | Open-market buy | $570,44253,613 shares | Aug 24, 2026 | Hayden Michael R | $570,442 | Open-market buy | 53,613 | Aug 24, 2026 |
| Montalbano John S.— | Open-market buy | $110,30010,000 shares | Aug 18, 2026 | Montalbano John S. | $110,300 | Open-market buy | 10,000 | Aug 18, 2026 |
| Booth AndrewChief Financial Officer | Open-market buy | $383,90437,200 shares | Aug 14, 2026 | Booth AndrewChief Financial Officer | $383,904 | Open-market buy | 37,200 | Aug 14, 2026 |
| Hayden Michael R— | Open-market buy | $481,03346,387 shares | Aug 14, 2026 | Hayden Michael R | $481,033 | Open-market buy | 46,387 | Aug 14, 2026 |
| Hayden Michael R— | Gift | nothing paid50,000 shares | Aug 13, 2026 | Hayden Michael R | nothing paid | Gift | 50,000 | Aug 13, 2026 |